Gilead (GILD) Veklury Retains Activity Against Omicron Variant - Entrepreneur

Retrieved on: 2022-02-14 23:09:10

Tags for this article:

Life Sciences

COVID-19 drug development

Drugs

Medical specialties

Monoclonal antibodies

Antiviral drugs

Zoonoses

Remdesivir

Casirivimab/imdevimab

SARS-CoV-2 Omicron variant

Sotrovimab

Bamlanivimab/etesevimab

Click the tags to see associated articles and topics

Gilead (GILD) Veklury Retains Activity Against Omicron Variant - Entrepreneur. View article details on HISWAI: https://www.entrepreneur.com/article/418526

Excerpt

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro ...

Article found on: www.entrepreneur.com

View Original Article